Table I.
Selected recent clinical trials in OC that use antibodies/immunotoxins or cytokines.
| Clinical trial approach | Clinical trial | # OC patients | Objective responses | Reference or Trial ID |
|---|---|---|---|---|
| Antibodies and Immunotoxins | Phase II trial of farletuzumab (anti-folate receptor) ± carboplatin or a taxane, 2013 | 54 | 44 – CR/PR 10 – PD or NA |
33 |
| Phase I trial of farletuzumab, 2010 | 25 | 9 – SD 15 – PD 1 – N/A |
34 | |
| Phase II trial of ipilimumab (anti-CTLA-4) ongoing | N/A | N/A | NCT01611558 | |
| Phase I trial of BMS-936559 (anti-PD-L1), 2012 | 17 | 1 – PR 3 – SD 13 - PD |
37 | |
| Phase II trial of oregovomab ± paclitaxel or paclitaxel/carboplatin, ongoing | N/A | N/A | NCT01616303 | |
| Phase III trial of abagovomab (anti-CA-125 idiotype), 2013 | 888 | No change in recurrence free or overall survival | 43 | |
| Phase II trial of volociximab (anti-α5β1 integrin), 2011 | 16 | 1 – SD 15 - PD |
45 | |
| Phase I trial of amatuximab (MORAb-009, anti-mesothelin), 2010 | 4 | 0 – CR/PR | 47 | |
| Phase 0/I trial of denileukin diftitox (IL-2/diphtheria fusion toxin), 2005 | 4 | 1 PR (trial did not have therapeutic intent and other patients were not evaluated for clinical endpoints) | 58 | |
| Phase II trial of denileukin diftitox, 2011 | 28 | 26-PD 2-SD |
58 | |
| Phase I trial of siltuximab (anti-IL-6 receptor), ongoing | N/A | N/A | NCT00841191 | |
| Cytokines | Phase II trial of NGR-hTNF+ doxorubicin, 2012 | 35 | 8 – PR 15 – SD 7 – PD |
87 |
| Phase I trial of IL-18 + pegylated liposomal doxorubicin, 2013 | 15 | 1 – PR 6 – SD 8 - PD |
88 | |
| Phase II trial of denileukin diftitox plus subcutaneous pegylated interferon-α, 2011 | 3 | 2-SD 1-PD |
71 |
Abbreviations: PD, progressive disease; IR, initial response; CR, complete response; CCR, continued clinical response; PR, partial response; SD, stable disease; NED, no evidence of disease; NR, no response; N/A, not available; PFS, progression-free survival; OS, overall survival.